Corcept Therapeutics Incorporated provided revenue guidance for the year 2024. The company expects revenue growth to continue and are reiterating 2024 revenue guidance of $600 million to $630 million compared to 2023 revenue of $482.4 million.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
28.85 USD | +6.69% | +20.28% | -11.24% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.24% | 2.82B | |
+29.49% | 684B | |
+30.34% | 568B | |
-3.94% | 361B | |
+17.58% | 329B | |
+4.14% | 284B | |
+16.21% | 240B | |
+9.66% | 208B | |
-6.83% | 200B | |
+6.94% | 166B |
- Stock Market
- Equities
- CORT Stock
- News Corcept Therapeutics Incorporated
- Corcept Therapeutics Incorporated Provides Revenue Guidance for the Year 2024